

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 13F

FORM 13F COVER PAGE

OMB APPROVAL

OMB Number:	3235-0006
Expires:	Oct 31, 2018
Estimated average burden hours per response:	23.8

Report for the Calendar Year or Quarter Ended: 03-31-2022

Check here if Amendment  Amendment Number:  
This Amendment (Check only one.): is a restatement.   
adds new holdings entries.

Institutional Investment Manager Filing this Report:

Name: JOHNSON & JOHNSON  
Address: ONE JOHNSON & JOHNSON PLZ  
NEW BRUNSWICK, NJ 08933

Form 13F File Number: 028-20072

The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.

Person Signing this Report on Behalf of Reporting Manager:

Name: Matthew Orlando  
Title: Secretary  
Phone: 732-524-2455

Signature, Place, and Date of Signing:

/s/ Matthew Orlando New Brunswick, NJ 05-09-2022  
[Signature] [City, State] [Date]

Report Type (Check only one.):

13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)

13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).)

13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).)

Form 13F Summary Page

Report Summary:

Number of Other Included Managers:	2
Form 13F Information Table Entry Total:	22
Form 13F Information Table Value Total:	528,967

(thousands)

List of Other Included Managers:

Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report.

[If there are no entries in this list, state "NONE" and omit the column headings and list entries.]

No.	Form 13F File Number	Name
1	028-20073	Johnson & Johnson Innovation - JJDC, Inc.
2	028-21422	Johnson & Johnson UK Treasury Co Ltd

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL	
OMB Number:	3235-0006
Expires:	Oct 31, 2018
Estimated average burden hours per response:	23.8

COLUMN 1	COLUMN 2	COLUMN 3	COLUMN 4	COLUMN 5			COLUMN 6	COLUMN 7	COLUMN 8		
NAME OF ISSUER	TITLE OF CLASS	CUSIP	VALUE (x\$1000)	SHRS OR PRN AMT	SH/ PUT/ CALL	INVESTMENT DISCRETION	OTHER MANAGER	SOLE	SHARED	NONE	
Adicet Bio, Inc.	COM	007002108	14,557	728,944	SH	DFND	1	0	728,944	0	
Aldeyra Therapeutics, Inc.	COM	01438T106	1,755	394,834	SH	DFND	1	0	394,834	0	
Arrowhead Pharmaceuticals, Inc.	COM	04280A100	57,987	1,260,869	SH	DFND	1	0	1,260,869	0	
BiomX Inc.	COM	09090D103	4,117	2,133,402	SH	DFND	1	0	2,133,402	0	
Catalyst Biosciences, Inc.	COM	14888D208	44	66,951	SH	DFND	1	0	66,951	0	
Cue Health, Inc.	COM	229790100	35,790	5,548,864	SH	DFND	1	0	5,548,864	0	
CVRx, Inc.	COM	126638105	20,938	3,495,575	SH	DFND	1	0	3,495,575	0	
Fate Therapeutics, Inc.	COM	31189P102	131,006	3,379,064	SH	DFND	1	0	3,379,064	0	
Fusion Pharmaceuticals Inc.	COM	36118A100	28,520	3,670,516	SH	DFND	1	0	3,670,516	0	
Graybug Vision, Inc.	COM	38942Q103	61	49,547	SH	DFND	1	0	49,547	0	
Legend Biotech Corporation	ADS	52490G102	59,204	1,629,173	SH	DFND	1	0	1,629,173	0	
MeiraGTx Holdings plc	COM	G59665102	40,145	2,898,550	SH	DFND	1	0	2,898,550	0	
Nano-X Imaging Ltd.	ORD SHS	M70700105	2,086	192,429	SH	DFND	1	0	192,429	0	
PhaseBio Pharmaceuticals, Inc.	COM	717224109	2,121	1,607,044	SH	DFND	1	0	1,607,044	0	
Point Biopharma Global Inc.	COM	730541109	7,970	1,000,000	SH	DFND	1	0	1,000,000	0	
Procept BioRobotics Corporation	COM	74276L105	35,637	1,018,478	SH	DFND	1	0	1,018,478	0	
Protagonist Therapeutics Inc.	COM	74366E102	57,997	2,449,183	SH	DFND	1	0	2,449,183	0	
Senseonics Holdings, Inc.	COM	81727U105	108	54,621	SH	DFND	1	0	54,621	0	
Tracon Pharmaceuticals,	COM	89237H209	221	84,003	SH	DFND	1	0	84,003	0	

Inc.									
Vor Biopharma, Inc.	COM	929033108	6,491	1,074,658	SH	DFND	1	0	1,074,658 0
Xencor, Inc.	COM	98401F105	19,958	748,062	SH	DFND	1	0	748,062 0
SomaLogic, Inc.	COM	83444K105	2,254	281,052	SH	DFND	N/A	0	281,052 0